Cervical Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 47 expanded access programs, clinical trials, and compassionate use pathways listed for Cervical Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with cervical cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 12 programs are currently active or recruiting, with the remaining 35 in other lifecycle stages. Sponsors actively running programs in this area include Merck Sharp & Dohme LLC, AstraZeneca, Christian Hinrichs, M.D. Anderson Cancer Center, University of Texas Southwestern Medical Center, and others.
By recruiting status
Snapshot of where every Cervical Cancer program currently sits in its lifecycle.
- Active / Recruiting12
- Inactive35
Top sponsors
Organisations running the most Cervical Cancer programs in the directory.
- Merck Sharp & Dohme LLC3 programs
- AstraZeneca2 programs
- Christian Hinrichs2 programs
- M.D. Anderson Cancer Center2 programs
- University of Texas Southwestern Medical Center2 programs
- Abramson Cancer Center at Penn Medicine1 program
- Agenus Inc.1 program
- Bristol-Myers Squibb1 program
- Daiichi Sankyo1 program
- Diwakar Davar1 program
Cervical Cancer programs (47)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 177Lu-BetaBart for Patients with Advanced or Hard-to-Treat Solid Tumors — Radiopharm Theranostics, Ltd
- Study on Sacituzumab Tirumotecan and Pembrolizumab for First-line Maintenance Treatment of Cervical Cancer — Merck Sharp & Dohme LLC
- Study on TER-2013 for Patients with Advanced Solid Tumors with Specific Genetic Changes — Terremoto Biosciences Inc.
- Study on Ivonescimab for Treating Endometrial and Cervical Cancers — Memorial Sloan Kettering Cancer Center
- Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
- Study on E7 T-Cell Therapy for Advanced HPV-Related Cancers — Christian Hinrichs
- Eye Health Monitoring in Patients Using Tivdak® for Recurrent or Metastatic Cervical Cancer — Pfizer
- Study on Patient Preference for Subcutaneous vs. Intravenous Immune Therapy — Diwakar Davar
- Phase II Study of AK104 for Recurrent Neuroendocrine Cervical Cancer — M.D. Anderson Cancer Center
- Study on Combining Radiation with Tarlatamab for DLL3 Expressing Tumors — University of Arizona
- Study on Volrustomig Alone or with Other Cancer Drugs for Advanced Solid Tumors — AstraZeneca
- Study on SPEDOX-6 for Advanced Cancers — University of California, Irvine
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on [225Ac]-FPI-1434 Injection for Patients with Advanced Solid Tumors — Fusion Pharmaceuticals Inc.
- Phase 2 Study of Avutometinib (VS-6766) and Defactinib for Gynecological Cancers — University of Oklahoma
- Study on Combination Immunotherapy for Advanced Cancers, Including HPV-Related, Small Bowel, and Colon Cancers — National Cancer Institute (NCI)
- Study on the Safety and Effectiveness of NC410 and Pembrolizumab for Advanced Solid Tumors — NextCure, Inc.
- Study on BMS-986340 Alone and with Nivolumab or Docetaxel for Advanced Solid Tumors — Bristol-Myers Squibb
- Study on HER3-DXd for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
- Study on Sacituzumab Govitecan for Patients with Recurrent or Persistent Cervical Cancer — Yale University
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) — Merck Sharp & Dohme LLC
- Study on MDX2001 for Patients with Advanced Solid Tumors — ModeX Therapeutics, An OPKO Health Company
- Dostarlimab and Cobolimab in Advanced Cervical Cancer — Meghan Shea
- E7 TCR-T Cell Immunotherapy for HPV-Related Cancers — Christian Hinrichs
- Study on the Effectiveness and Safety of VB10.16 Alone or with Atezolizumab in Patients with Advanced Cervical Cancer — Nykode Therapeutics ASA
- Study on the Duration of PD-1/PD-L1 Inhibitor Treatment in Advanced Solid Tumors — Jason J. Luke, MD
- Study on GI-101 Alone or with Pembrolizumab, Lenvatinib, or Local Radiotherapy for Advanced Solid Tumors — GI Innovation, Inc.
- Study on Glutaminase Inhibition and Chemoradiation for Advanced Cervical Cancer — Washington University School of Medicine
- Study on Oral Q702 and Pembrolizumab for Advanced Esophageal, Gastric, Liver, and Cervical Cancers — Qurient Co., Ltd.
- Study on Pembrolizumab and Lenvatinib for Advanced Cervical Cancer — Georgetown University
- Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer — University of Texas Southwestern Medical Center
- Study on PRGN-2009 and Pembrolizumab Combination vs. Pembrolizumab Alone for Recurrent or Metastatic Cervical Cancer — Precigen, Inc
- Proton Therapy for Post-Surgery Treatment of Gynecologic Cancer — Abramson Cancer Center at Penn Medicine
- Study on Combination Immunotherapies for Patients Previously Treated with Immune Checkpoint Inhibitors — ImmunityBio, Inc.
- Study on Anti-PD-1 Alone or with Anti-CTLA-4 for Second-Line Treatment in Cervical Cancer — Agenus Inc.
- Study on the Safety and Effectiveness of NEO212 for Patients with Certain Brain Tumors or Brain Metastasis — Neonc Technologies, Inc.
- Study on Tisotumab Vedotin Alone and Combined with Other Cancer Drugs for Cervical Cancer — Seagen, a wholly owned subsidiary of Pfizer
- Study on the Safety and Effects of ONC-392 Alone and with Anti-PD-1 in Advanced Solid Tumors and Non-Small Cell Lung Cancer — OncoC4, Inc.
- Study on Using SBRT and Atezolizumab for Treating Recurrent, Persistent, or Metastatic Cervical Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Study of AZD5305 Alone and with Other Cancer Treatments in Patients with Advanced Solid Tumors — AstraZeneca
- Study of NEO-201 in Solid Tumors Expansion Groups — Precision Biologics, Inc
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study of Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors — Merck Sharp & Dohme LLC
- Study of Pembrolizumab and Lenvatinib for Advanced Cervical Cancer — University of Texas Southwestern Medical Center
- Study on TNG260 and an Anti-PD Antibody for Solid Tumors with STK11 Mutation — Tango Therapeutics, Inc.
- Study on the Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, in People Living with HIV — Weill Medical College of Cornell University
- Study on Immunotherapy Induction for Advanced Cervical Cancer (TRACTION) — M.D. Anderson Cancer Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Cervical Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.